AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. – 22. (Canceled)

23. (Previously presented). A compound of the following formula I, or a pharmaceutically



acceptable salt thereof:

(I)

wherein:

R^1 and R^2 are each independently selected from the group consisting of H, F, Cl, Br, I, NO_2, CF_3, CN, OCF_3, OH, C_1-C_4alkoxy-, C_1-C_4alkylcarbonyl-, C_1-C_6 alkyl, hydroxy C_1-C_4 alkyl-, C_3-C_6 alkenyl, C_3-C_6 alkynyl, C_3-C_{10} cycloalkyl(C_0-C_4alkyl)-, $H_2N(C_0$-$C_4)$alkyl-, $R^6HN(C_0$-$C_4)$alkyl-, $R^6R^7N(C_0$-$C_4)$alkyl-, $R^7S(C_0$-$C_4)$alkyl-, $R^7S(O)$ $(C_0$-$C_4)$alkyl-, $R^7SO_2(C_0$-$C_4)$alkyl-, $R^6NSO_2(C_0$-$C_4)$alkyl-, HSO_3, $HO_2C(C_0$-$C_4)$alkyl-, $R^6O_2C(C_0$-$C_4)$alkyl-, and $R^6R^7NCO(C_0$-$C_4)$alkyl-,

or R^1 and R^2, when on adjacent carbon atoms, and when taken together are methylenedioxy or ethylenedioxy;

R^5 is independently selected from H, F, Cl, Br, I, NO_2, CN, CF_3, OCF_3, OH, C_1-C_4alkoxy-, hydroxyC_1-C_4 alkyl-, C_1-C_4 alkylcarbonyl-, CO_2H, CO_2R^6, $CONR^6R^7$, NHR^6, and NR^6R^7;

R^6 is selected from H, C_1-C_8 alkyl, C_3-C_6 alkenyl, C_3-C_6 alkynyl, C_3-C_{10} cycloalkyl(C_0-C_4 alkyl)-, aryl(C_0-C_4 alkyl)-, and heterocyclic (C_0-C_4 alkyl)-,

wherein said aryl or heterocyclic groups are substituted with 0-2 substituents independently selected from C_1-C_4 alkyl, C_1-C_4 alkoxy, hydroxy C_0-C_4 alkyl, oxo, F, Cl, Br, CF_3, NO_2, CN, OCF_3, NH_2, NHR^7, NR^7R^8, SR^7, $S(O)R^7$, SO_2R^7, $SO_2NR^7R^8$, CO_2H, CO_2R^7, and $CONR^7R^8$;

R^7 and R^8 are each independently selected from H, C_1-C_8 alkyl, C_3-C_6 alkenyl, C_3-C_6 alkynyl, C_3-C_{10} cycloalkyl(C_0-C_4 alkyl)-, C_1-C_6 alkylcarbonyl, C_3-C_7 cycloalkyl(C_0-C_5 alkyl)carbonyl, C_1-C_6 alkoxycarbonyl, C_3-C_7 cycloalkyl(C_0-C_5 alkoxy)carbonyl, aryl(C_1-C_5 alkoxy)carbonyl, arylsulfonyl, aryl(C_0-C_4 alkyl)-, heterocyclic(C_1-C_5 alkoxy)carbonyl, heterocyclic sulfonyl and heterocyclic (C_0-C_4 alkyl)-, wherein said aryl or heterocyclic groups are substituted with 0-2 substituents independently selected from the group consisting of C_1-C_4 alkyl, C_1-C_4 alkoxy, F, Cl, Br, CF_3, CN, and NO_2;

or R^6 and R^7, or R^6 and R^8, or R^7 and R^8, when both substituents are on the same nitrogen atom, do or do not form, with the nitrogen atom to which they are attached, a heterocycle selected from 1-aziridinyl, 1-azetidinyl, 1-piperidinyl, 1-morpholinyl, 1-pyrrolidinyl, thiamorpholinyl, thiazolidinyl, and 1-piperazinyl, said heterocycle is unsubstituted or substituted with 0-3 groups selected from oxo, C_1-C_6 alkyl, C_3-C_7 cycloalkyl(C_0-C_4 alkyl)-, C_1-C_6 alkylcarbonyl, C_3-C_7 cycloalkyl(C_0-C_5 alkyl)carbonyl, C_1-C_6 alkoxycarbonyl, C_3-C_7 cycloalkyl(C_0-C_5 alkoxy)carbonyl, aryl(C_0-C_5 alkyl), heterocyclic(C_0-C_5 alkyl), aryl(C_1-C_5 alkoxy)carbonyl, heterocyclic(C_1-C_5 alkoxy)carbonyl, C_1-C_6 alkylsulfonyl, arylsulfonyl, and heterocyclicsulfonyl,

wherein said aryl or heterocyclic groups are substituted with 0-2 substituents independently selected from C_1-C_4 alkyl, C_1-C_4 alkoxy, F, Cl, Br, CF_3, CN, and NO_2;

K is selected from -C(=O)- and $-CHR^9$-;

L is selected from -C(=O), $-CHR^9$-, $-CR^{10}R^{11}$-, $-CR^{10}R^{11}$-(C=O), $-HR^{15}C$-CHR^{16}-, and -$R^{15}C$=CR^{16};

R^9 is selected from H, C_1-C_8 alkyl, C_3-C_6 alkenyl, C_3-C_{10} cycloalkyl(C_0-C_4 alkyl)-, aryl(C_0-C_4 alkyl)-, and heterocyclic(C_0-C_4 alkyl)-,

wherein said aryl or heterocyclic groups are substituted with 0-2 substituents independently selected from C_1-C_4 alkyl, C_1-C_4 alkoxy, F, Cl, Br, CF_3, and NO_2;

R^{10} is selected from H, F, Cl, Br, C_1-C_6 alkoxy, C_1-C_8 alkyl, C_3-C_6 alkenyl, C_3-C_{10} cycloalkyl(C_0-C_4 alkyl)-, aryl(C_0-C_4 alkyl)-, and heterocyclic(C_0-C_4 alkyl)-, wherein said aryl or heterocyclic groups are substituted with 0-2 substituents independently selected from C_1-C_4 alkyl, C_1-C_4 alkoxy, F, Cl, Br, CF_3, CN, and NO_2;

R^{11} is selected from H, F, Cl, Br, OMe, C_1-C_8 alkyl, C_3-C_6 alkenyl, C_3-C_{10} cycloalkyl(C_0-C_4 alkyl)-, aryl(C_0-C_4 alkyl)-, and heterocyclic(C_0-C_4 alkyl)-, wherein said aryl or heterocyclic groups are substituted with 0-2 substituents independently selected from C_1-C_4 alkyl, C_1-C_4 alkoxy, F, Cl, Br, CF_3, CN, and NO_2;

or R^{10} and R^{11}, when on the same carbon atom, do or do not form, with the carbon atoms to which they are attached, a 3-7 membered carbocyclic or 3-7 membered heterocyclic non-aromatic ring system, said carbocyclic or heterocyclic ring is unsubstituted or substituted with 0-2 substituents independently selected from C_1-C_4 alkyl, C_1-C_4 alkoxy, hydroxy C_0-C_4 alkyl, oxo, F, Cl, Br, CF_3, and NO_2;

R^{12} is selected from H, C_3-C_6 alkenyl, C_3-C_{10} cycloalkyl(C_0-C_4 alkyl)-, monocyclic or bicyclic 5-10 membered heterocyclic(C_0-C_4 alkyl)-, and $-CZ^1Z^2Z^3$, provided $-CZ^1Z^2Z^3$ is not C_1-C_8 alkyl,

wherein said aryl or heterocyclic groups are substituted with 0-3 substituents independently selected from R^{14};

Z^1 is selected from C_1-C_8 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 hydroxyalkyl, C_1-C_4 alkoxy C_1-C_4 alkyl, aryl(C_0-C_4 alkyl)-, and 4-10 membered heterocyclic (C_0-C_4 alkyl)-,

wherein said aryl or heterocyclic groups are substituted with 0-3 substituents independently selected from R^{14};

Z^2 is selected from C_1-C_8 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 hydroxyalkyl, C_1-C_4 alkoxy C_1-C_4 alkyl, C_1-C_6 $NR^{17}R^{18}$, aryl(C_0-C_4 alkyl)-, and 4-10 membered heterocyclic (C_0-C_4 alkyl)-,

wherein said aryl or heterocyclic groups are substituted with 0-3 substituents independently selected from R^{14};

Z^3 is selected from C_1-C_8 alkyl, R^{14}(C_2-C_4 alkyl)-, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 hydroxyalkyl, C_1-C_4 alkoxy C_1-C_4 alkyl, aryl(C_0-C_4 alkyl)-, 4-10 membered heterocyclic (C_0-C_4 alkyl)-, $R^{17}O{=}C(C_0$-C_4 alkyl)-, $R^{17}OO{=}C(C_0$-C_4 alkyl)-, and $R^{17}R^{18}$ $NO{=}C(C_0$-C_4 alkyl)-,

wherein said aryl or heterocyclic groups are substituted with 0-3 substituents independently selected from R^{14};

or Z^1 and Z^2, when on the same carbon atom, may form, with the carbon atoms to which they are attached, a 3-7 membered carbocyclic or 3-7 membered heterocyclic non-aromatic ring system, said carbocyclic or heterocyclic ring may be substituted with 0-2 substituents independently selected from R^{14}[.];

R^{13} is selected from H, C_1-C_8 alkyl, C_3-C_6 alkenyl, C_3-C_{10} cycloalkyl(C_0-C_4 alkyl)-, C_1-C_6 alkylcarbonyl, C_1-C_6 alkylsulfonyl, C_3-C_7 cycloalkyl(C_0-C_5 alkyl)carbonyl, C_1-C_6 alkoxycarbonyl, C_3-C_7 cycloalkyl(C_0-C_5 alkoxy)carbonyl, aryl(C_0-C_4 alkyl)-, aryl(C_1-C_5 alkoxy)carbonyl , arylsulfonyl, heterocyclic(C_0-C_4 alkyl), heterocyclic(C_1-C_5 alkoxy)carbonyl, and heterocyclicsulfonyl,

wherein said aryl or heterocyclic groups are substituted with 0-2 substituents independently selected from C_1-C_4 alkyl, C_1-C_4 alkoxy, F, Cl, Br, CF_3, CN, and NO_2;

R^{14} is selected from H, C_1-C_{10} alkyl, NO_2, CF_3, CN, F, Cl, Br, C_1-C_{10} alkylcarbonyl, haloalkyl, haloalkoxy, OH, NR^6R^7(C_0-C_4 alkyl)-, R^6 $C(=O)O(C_0$-C_4 alkyl)-, $R^6OC(=O)O$ (C_0-C_4 alkyl)-, R^6O (C_0-C_4 alkyl), R^6R^7 $NC(=O)$ $O(C_0$-C_4 alkyl)-, R^6R^7 $NC(=O)$ (C_0-C_4 alkyl)-, $R^6O(CR^{10}R^{11})_{2\text{-}6}R^6NC(=O)$ (C_0-C_4 alkyl)-, $R^6R^7N(CR^{10}R^{11})_{2\text{-}6}R^6NC(=O)$ (C_0-C_4 alkyl)-, $R^6O_2C(CH_2)_{1\text{-}4}O(C_0$-$C_4$ alkyl)-, $R^6OOC(C_1$-C_4 alkoxy),- $R^6OOC(C_0$-C_4 alkyl)-, $R^6C(=O)(C_0$-C_4 alkyl)-, $R^6C(=O)NR^7(C_0$-C_4 alkyl)-, $R^6OC(=O)NR^7(C_0$-C_4 alkyl)-, $R^6OC(=NCN)NR^7(C_0$-C_4 alkyl)-, $R^6R^7NC(=O)NR^8(C_0$-C_4 alkyl)-, $R^6OC(=NC)$ $NR^7(C_0$-C_4 alkyl)-, $R^6(CR^{10}R^{11})_{1\text{-}4}$ $NR^7C{=}O$-, R^6O $(CR^{10}R^{11})_{1\text{-}4}O{=}CR^7N$-, $NR^6R^7(CR^{10}R^{11})_{1\text{-}4}$ $C{=}O$ R^7N-, $R^6O(CR^{10}R^{11})_{2\text{-}4}R^7N$-, $R^6O_2C(CR^{10}R^{11})_{1\text{-}4}R^7N$, R^6R^7N $(CR^{10}R^{11})_{2\text{-}4}R^7N$-, $R^6R^7NC(=NCN)NR^7(C_0$-C_4 alkyl)-, $R^6R^7NC(=C(H)(NO_2))NR^7(C_0$-$C_4$ alkyl)-, R^7R^8N $C(=NR^7)$ $NR^7(C_0$-C_4 alkyl)-, R^6R^7N $SO_2NR^8(C_0$-C_4 alkyl)-, $R^6SO_2NR^7(C_0$-C_4

alkyl)-, $R^6R^7N(C_1\text{-}C_4)$ CO-, $R^6R^7N(C_2\text{-}C_6$ alkyl)O-, $R^6CO(CR^{10}R^{11})_{0\text{-}2}$ $R^7N(O_2)S(C_0\text{-}C_4$ alkyl), $R^6(O_2)S$ R^7 NC(=O) ($C_0\text{-}C_4$ alkyl)-, $R^6S(C_0\text{-}C_4$ alkyl)-, R^6S(=O) ($C_0\text{-}C_4$ alkyl)-, $R^6SO_2(C_0\text{-}C_4$ alkyl)-, $SO_2NR^6R^7$, $SiMe_3$, $R^6R^7N(C_2\text{-}C_4$ alkyl)-, $R^6R^7N(C_2\text{-}C_4$ alkoxy)-, HSO_3, HONH-, R^6ONH-, $R^8R^7NNR^6$-, $HO(COR^6)N$-, $HO(R^6O_2C)N$, $C_2\text{-}C_6$ alkenyl, $C_3\text{-}C_{10}$ cycloalkyl, $C_3\text{-}C_{10}$ cycloalkylmethyl, aryl($C_0\text{-}C_4$alkyl)-, heteroaryl($C_0\text{-}C_4$alkyl)-, aryl($C_0\text{-}C_4$alkyl)O-, and heteroaryl($C_0\text{-}C_4$alkyl)O-,

wherein said aryl groups are substituted with 0-2 substituents independently selected from $C_1\text{-}C_4$ alkyl, $C_1\text{-}C_4$ alkoxy, F, Cl, Br, CF_3, and NO_2;

R^{15} is selected from H, halo, cyano, $C_1\text{-}C_8$ alkyl, $C_3\text{-}C_6$ alkenyl, and $C_3\text{-}C_{10}$ cycloalkyl($C_0\text{-}C_4$ alkyl)-, aryl($C_0\text{-}C_4$ alkyl)-, and heterocyclic($C_0\text{-}C_4$ alkyl)-,

wherein said aryl or heterocyclic groups are substituted with 0-2 substituents independently selected from R^{14}; and

R^{16} is selected from H, halo, cyano, $C_1\text{-}C_8$ alkyl, $C_3\text{-}C_6$ alkenyl, $C_3\text{-}C_{10}$ cycloalkyl($C_0\text{-}C_4$ alkyl)-, aryl($C_0\text{-}C_4$ alkyl)-, and heterocyclic($C_0\text{-}C_4$ alkyl)-,

wherein said aryl or heterocyclic groups are substituted with 0-2 substituents independently selected from R^{14};

or when R^{15} and R^{16} are on adjacent carbon atoms, or when R^{15} and R^{16} are oriented on the same side of the double bond, as depicted in the following structure (III)



(III),

R^{15} and R^{16} do or do not form, with the carbon atoms to which they are attached, a 3-7 membered carbocyclic aromatic or nonaromatic ring system, or a 3-7 membered heterocyclic aromatic or nonaromatic ring system, said carbocyclic or heterocyclic ring is unsubstituted or substituted with 0-2 substituents independently selected from $C_1\text{-}C_4$ alkyl, $C_1\text{-}C_4$ alkoxy, F, Cl, Br, CF_3,and NO_2;

R^{17} is selected from H, $C_1\text{-}C_8$ alkyl, $C_3\text{-}C_6$ alkenyl, $C_3\text{-}C_{10}$ cycloalkyl($C_0\text{-}C_4$ alkyl)-, $C_1\text{-}C_6$ alkylcarbonyl, $C_1\text{-}C_6$ alkylsulfonyl, $C_3\text{-}C_7$ cycloalkyl($C_0\text{-}C_5$ alkyl)carbonyl, $C_1\text{-}C_6$ alkoxycarbonyl, $C_3\text{-}C_7$ cycloalkyl($C_0\text{-}C_5$ alkoxy)carbonyl, hydroxy($C_2\text{-}C_4$)alkyl-, $C_1\text{-}C_3$ alkoxy($C_2\text{-}C_4$)alkyl-, ($C_0\text{-}C_4$ alkyl) ($C_0\text{-}C_4$ alkyl) amino($C_2\text{-}C_4$)alkyl-, aryl($C_0\text{-}C_4$ alkyl)-, aryl($C_1\text{-}C_5$ alkoxy)carbonyl ,

arylsulfonyl, heterocyclic(C_0-C_4 alkyl), heterocyclic(C_1-C_5 alkoxy)carbonyl, and heterocyclicsulfonyl,

wherein said aryl or heterocyclic groups are substituted with 0-2 substituents independently selected from C_1-C_4 alkyl, C_1-C_4 alkoxy, C_1-C_4 alkoxy C_1-C_4 alkyl, oxo, F, Cl, Br, CF_3, CN, and NO_2; and

R^{18} is selected from H, C_1-C_8 alkyl, C_3-C_6 alkenyl, C_3-C_{10} cycloalkyl(C_0-C_4 alkyl)-, aryl(C_0-C_4 alkyl)-, and heterocyclic(C_0-C_4 alkyl),

wherein said aryl or heterocyclic groups are substituted with 0-2 substituents independently selected from C_1-C_4 alkyl, C_1-C_4 alkoxy, F, Cl, Br, CF_3, CN, and NO_2;

or R^{17} and R^{18}, when both are on the same nitrogen atom, may form, with the nitrogen atom to which they are attached, a heterocycle selected from 1-aziridinyl, 1-azetidinyl, 1-piperidinyl, 1-morpholinyl, 1-pyrrolidinyl, thiamorpholinyl, thiazolidinyl, and 1-piperazinyl,

said heterocycle may be substituted with 0-3 groups selected from oxo, C_1-C_6 alkyl, C_3-C_7 cycloalkyl(C_0-C_4 alkyl)-, C_1-C_6 alkylcarbonyl, (C_1-C_6 alkylcarbonyl)(C_0-C_4alkyl)amino-, C_3-C_7 cycloalkyl(C_0-C_5 alkyl)carbonyl, C_1-C_6 alkoxycarbonyl, C_3-C_7 cycloalkyl(C_0-C_5 alkoxy)carbonyl, aryl(C_0-C_5 alkyl), heterocyclic(C_0-C_5 alkyl), aryl(C_1-C_5 alkoxy)carbonyl, heterocyclic(C_1-C_5 alkoxy)carbonyl, C_1-C_6 alkylsulfonyl arylsulfonyl and heterocyclicsulfonyl,

wherein said aryl or heterocyclic groups are substituted with 0-2 substituents independently selected from CH_3-, alkoxy, F, Cl, Br, CF_3, CN, and NO_2.

24. (Previously presented). A compound or pharmaceutically acceptable salt thereof of Claim 23 having the formula,



wherein

R^1 and R^2 are each independently selected from the group consisting of H, F, Cl, Br, I, NO_2, CF_3, CN, OCF_3, OH, C_1-C_4alkoxy-, and C_1-C_4alkyl-;

R^5 is selected from the group consisting of H, F, Cl, Br, I, NO_2, CN, CF_3, OCF_3, OH, C_1-C_4alkoxy, and CO_2H; and

R^7 is selected from hydrogen and C_1-C_8 alkyl.

25. (Previously presented). The compound or a pharmaceutically acceptable salt thereof of Claim 24 wherein

R^5 is H;

R^1 is selected from the group consisting of OCF_3 and C_1-C_4alkoxy;

R^2 is H; and

R^{13} is hydrogen.

26. (Previously presented). The compound or a pharmaceutically acceptable salt thereof of Claim 25 wherein:

K is C(=O); and

L is C(=O).

27. (Previously presented). The compound or a pharmaceutically acceptable salt thereof of Claim 26 having the formula,



wherein R^{12} is $-CZ^1Z^2Z^3$.

28. (Previously presented). The compound or a pharmaceutically acceptable salt thereof of Claim 27 wherein:

R^7 is hydrogen; and

R^1 is methoxy.

29. (Previously presented). The compound or a pharmaceutically acceptable salt thereof of Claim 28 wherein Z^1 and Z^2 are independently selected from C_1-C_8 alkyl.

30. (Previously presented). The compound or a pharmaceutically acceptable salt thereof of Claim 25 wherein:

K is C(=O) and

L is CHR^9.

31. (Previously presented). A compound or a pharmaceutically acceptable salt thereof of Claim 25 wherein:

K is $CHR^9$and

L is C(=O).

32. (Previously presented). A compound or a pharmaceutically acceptable salt thereof of Claim 25 wherein:

K is C(=O) and

L is $-CR^{10}R^{11}-(C=O)$.

33. (Previously presented). A compound or pharmaceutically acceptable salt thereof, wherein said compound is selected from:

N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-(phenylmethyl)ethanediamide;

N-[1,1-Bis(hydroxymethyl)propyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

N-(2-Hydroxy-1,1-dimethylethyl)-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

N-[[[3-Methoxy-4-(5-oxazolyl)phenyl]amino]oxoacetyl]-2-methylalanine 1,1-dimethylethyl ester;

N-(2-Hydroxy-1,1-dimethylpentyl)-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

N-[2-[(2-Hydroxy-1,1-dimethylethyl)amino]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

N-[2-(Dimethylamino)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

N-(1,1-Diethyl-2-propynyl)-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

N-[1-(Hydroxymethyl)cyclopentyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

N-[2-(4-Fluorophenyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

N-[[[3-Methoxy-4-(5-oxazolyl)phenyl]amino]oxoacetyl]-α -methyltyrosine methyl ester;

N-[[[3-Methoxy-4-(5-oxazolyl)phenyl]amino]oxoacetyl]-a-methyltryptophan methyl ester;

N-[1,1-Bis(hydroxymethyl)ethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]-N-methylethanediamide;

N-(1,1-Dimethyl-3-oxobutyl)-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-(1-methyl-1-phenylethyl)ethanediamide;

N-(2-Hydroxy-1,2-dimethyl-1-phenylpropyl)-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

N-[[[3-Methoxy-4-(5-oxazolyl)phenyl]amino]oxoacetyl]-2-methylalanine methyl ester;

-[[[[3-Methoxy-4-(5-oxazolyl)phenyl]amino]oxoacetyl]amino]cyclopropanecarboxylic acid methyl ester;

N-(1-Ethynylcyclohexyl)-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

(R)-N-[1-(Hydroxymethyl)-1-methylpropyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]-N-methylethanediamide;

N-[[[3-Methoxy-4-(5-oxazolyl)phenyl]amino]oxoacetyl]-2-methylalanine;

N-[1,1-Dimethyl-2-oxo-2-(1-piperidinyl)ethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

N-[1,1-Dimethyl-2-(4-methyl-1-piperazinyl)-2-oxoethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

N-[1,1-Dimethyl-2-(4-morpholinyl)-2-oxoethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

4-[2-[[[[3-Methoxy-4-(5-oxazolyl)phenyl]amino]oxoacetyl]amino]-2-methyl-1-oxopropyl]-1-piperazinecarboxylic acid ethyl ester;

N-[2-[3-(Acetylmethylamino)-1-pyrrolidinyl]-1,1-dimethyl-2-oxoethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

N-[1,1-Dimethyl-2-[methyl[2-(methylamino)ethyl]amino]-2-oxoethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

N-[1,1-Dimethyl-2-oxo-2-(propylamino)ethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

N-[1,1-Dimethyl-2-[[2-(methylamino)ethyl]amino]-2-oxoethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

N-[1,1-Dimethyl-2-[[2-(4-morpholinyl)ethyl]amino]-2-oxoethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

N-[1,1-Dimethyl-2-oxo-2-[[3-(2-oxo-1-pyrrolidinyl)propyl]amino]ethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

N-[2-[[2-(1H-Imidazol-4-yl)ethyl]amino]-1,1-dimethyl-2-oxoethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

N-[2-[[2-(Acetylamino)ethyl]amino]-1,1-dimethyl-2-oxoethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

N-[2-[[2-(1H-Imidazol-1-yl)ethyl]amino]-1,1-dimethyl-2-oxoethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

N-[1,1-Dimethyl-2-oxo-2-[[2-(4-pyridinyl)ethyl]amino]ethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

N-[1,1-Dimethyl-2-oxo-2-[[(tetrahydro-2-furanyl)methyl]amino]ethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

N-[2-[(2-Methoxyethyl)amino]-1,1-dimethyl-2-oxoethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

N-[2-(Dimethylamino)-1,1-dimethyl-2-oxoethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

N-[2-[4-(2-Methoxyethyl)-1-piperazinyl]-1,1-dimethyl-2-oxoethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide; and

N-[1,1-Dimethyl-2-oxo-2-(2-pyridinylamino)ethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide.

34. (Previously presented). A pharmaceutical composition comprising a pharmaceutically acceptable carrier, adjuvant or vehicle and at least one compound of claim 23, or a pharmaceutically acceptable salt thereof, in an amount effective therefor.

35. – 39. (Canceled.)